As outlined below, HSP inhibition in MPN has provided promising results over the past few years, and several clinical trials evaluating the safety and efficacy of HSP90 inhibitors (PU-H71; NCT01393509 and NCT03935555) have recently been initiated (source: https://clinicaltrials.gov). Here, HSP90AB1 is linked to myeloproliferative neoplasm.